Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chromifem is a multi-ingredient nutraceutical product developed by Rowez Life Sciences, primarily indicated for the management of Polycystic Ovary Syndrome (PCOS) and associated metabolic and hormonal imbalances. The formulation typically contains a combination of myo-inositol, D-chiro-inositol, chromium picolinate, and folic acid. These components work synergistically to improve insulin sensitivity, restore ovulatory function, and regulate the menstrual cycle. Myo-inositol and D-chiro-inositol act as second messengers in insulin signaling, facilitating glucose uptake and reducing hyperinsulinemia. Chromium picolinate enhances the activity of the insulin receptor tyrosine kinase, further improving insulin action. Folic acid is included to support reproductive health and manage homocysteine levels. Together, these ingredients help address the underlying insulin resistance and hormonal disruptions characteristic of PCOS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chromifem.